



Supporting information

**This appendix was part of the submitted manuscript and has been peer reviewed.
It is posted as supplied by the authors.**

Appendix to: Hayes MW, Fung VSC, Kimber TE, O'Sullivan JD. Updates and advances in the treatment of Parkinson disease. *Med J Aust* 2019; doi: 10.5694/mja2.50224.

APPENDIX

The grading of the evidence base is based on the NHMRC Level of Evidence system (see below) and specialist society evidence-based reviews. We have not attempted to further grade the strength of the recommendation though these are discussed for non-motor symptoms in PD in a recent review: Seppi K, Ray Chaudhuri K, Coelho M, Fox S H, Katzenschlager R, Perez Lloret S et al. Update on treatments for non-motor symptoms of Parkinson's disease—an evidence-based medicine review. *Mov Disord* 2019; 34: 180-198.

	A	B	C	D
	Excellent	Good	Satisfactory	Poor
Evidence base	Several level I or II studies with low risk of bias	One or two level II studies with low risk of bias or a SR/multiple or level III studies with low risk of bias	level III studies with low risk of bias, or level I or II studies with moderate risk of bias	level IV studies with low risk of bias or level I to III studies with high risk of bias

Level I is defined as a systematic review of level II studies

Level II is defined as a randomised controlled trial

More detailed information can be obtained from the NHMRC levels of evidence and grades for recommendation website.